Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH

14-06-2018 | Lung cancer | ASCO 2018 | Video

Expert commentary: Lung cancer highlights, including the KEYNOTE-042 and CCGA studies

ASCO expert David Graham comments on the plenary KEYNOTE-042 trial, putting the findings in context of other recent research, and highlights the initial report from the CCGA study that could pave the way for a novel lung cancer screening approach. (5:02)
Image Credits